1,713 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Clearstead Trust LLC

Clearstead Trust LLC purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,713 shares of the medical research company’s stock, valued at approximately $131,000.

Several other large investors have also recently bought and sold shares of EW. Connecticut Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 26.0% in the fourth quarter. Connecticut Wealth Management LLC now owns 12,549 shares of the medical research company’s stock valued at $957,000 after acquiring an additional 2,589 shares in the last quarter. National Bank of Canada FI raised its position in shares of Edwards Lifesciences by 4.6% in the fourth quarter. National Bank of Canada FI now owns 214,861 shares of the medical research company’s stock valued at $16,234,000 after buying an additional 9,352 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its position in shares of Edwards Lifesciences by 13.1% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 6,834 shares of the medical research company’s stock valued at $521,000 after buying an additional 793 shares in the last quarter. Baxter Bros Inc. boosted its stake in shares of Edwards Lifesciences by 7.1% in the fourth quarter. Baxter Bros Inc. now owns 90,542 shares of the medical research company’s stock valued at $6,904,000 after buying an additional 5,985 shares during the period. Finally, Malaga Cove Capital LLC increased its stake in Edwards Lifesciences by 43.0% during the 4th quarter. Malaga Cove Capital LLC now owns 6,907 shares of the medical research company’s stock worth $527,000 after acquiring an additional 2,076 shares during the period. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on EW shares. Mizuho increased their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Finally, Piper Sandler boosted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Trading Up 0.2 %

NYSE:EW traded up $0.19 during trading hours on Friday, hitting $85.25. 2,327,197 shares of the company were exchanged, compared to its average volume of 3,001,614. The company has a fifty day simple moving average of $90.08 and a 200 day simple moving average of $79.46. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The stock has a market capitalization of $51.37 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Activity

In related news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now owns 4,486 shares in the company, valued at $388,801.62. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares in the company, valued at $388,801.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 237,749 shares of company stock valued at $20,920,934. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.